"For treatment of multiple sclerosis."@en . . " "@en . "# Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn's disease. N Engl J Med. 2003 Jan 2;348(1):24-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12510039 # Patent Information \"Link\":http://www.patentstorm.us/patents/5840299/fulltext.html"@en . . "Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006."@en . . . . "11 \u00B1 4 days"@en . . . . "Anti-alpha4 integrin"@en . . . "* 5.7 \u00B1 1.9 L [Multiple Sclerosis (MS) Patients] * 5.2 \u00B1 2.8 L [Crohn's Disease (CD) Patients]"@en . "189261-10-7"@en . "* 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose] * 22 +/- 22 mL/hour [Patients with Crohn's Disease receiving the repeat IV administration of a 300 mg dose]"@en . "Anti-VLA4"@en . . . . "Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s)."@en . . . . . . "Humans and other mammals"@en . "approved"@en . . "investigational"@en . "Natalizumab"@en .